Trials / Completed
CompletedNCT04343261
Convalescent Plasma in the Treatment of COVID 19
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 48 (actual)
- Sponsor
- Trinity Health Of New England · Academic / Other
- Sex
- All
- Age
- 18 Years – 90 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to collect blood from previously COVID-19 infected persons who have recovered and use it as a treatment for those who are currently sick with a severe or life-threatening COVID-19 infection.
Detailed description
The purpose of this prospective interventional study is to gain clinical experience using convalescent plasma transfusion administered to critically ill patients with COVID-19. 1 To study the efficacy of plasma from patients recovered from COVID-19 infection with a high neutralizing antibody titer (NAT) as treatment for individuals who are critically ill with COVID-19. 2\. Determine if the antibodies from convalescent plasma will suppress virus load in critically ill patients with COVID-19.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | Convalescent Plasma | treatment with 2 Units of convalescent plasma |
Timeline
- Start date
- 2020-04-10
- Primary completion
- 2020-07-23
- Completion
- 2020-08-13
- First posted
- 2020-04-13
- Last updated
- 2020-09-24
- Results posted
- 2020-09-17
Locations
1 site across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT04343261. Inclusion in this directory is not an endorsement.